Pharmaceutical research drug development process

In summary, there is a wealth of molecular information and stractural diversity available from a wide variety of suppliers of screening libraries. These resources are becoming more and more a key part of the pharmaceutical research and development process and are no longer simply regarded as a source of cheap or poor quality structures. Those providers who recognise the need for better quality molecules that fit descriptors for lead- or drug-likeness will be the ones who are likely to benefit the most from this recognition. In turn, those benefits will be passed back to the research and development community as a further improvement in supply and collaboration. 

Since that time, the pharmaceutical industry in the developed world has focused primarily on the synthesis of compounds for development as single agent prescription products. These efforts have required very substantial investments and, in the USA alone, investment in pharmaceutical research and development is probably close to 40 billion per year. In order to prevent the theft of a drug by an entity that has made no investment in the discovery and development research programme, companies have sought to protect their investments through the patent process. 

The ultimate focus of the endeavors of medicinal chemists is to develop a successful drug that will cure patients. However, with the increased regulatory requirements within the competitive biotechnology and pharmaceutical industry, the initial research to achieve this objective must be conducted in a rapid and thorough manner. During the drug research and development process, the important and subtle relationship between chirality and biological activity should be carefully considered. 

---